Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.
INTRODUCTION
Hepatitis C virus (HCV) infection is a disease of global health concern with an estimated worldwide prevalence of 71 million infected individuals. 1 Untreated HCV infection has been associated with significant morbidity and mortality, not only due to liver related complications but also to extrahepatic manifestations. The number of deaths related to chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic B and C viral hepatitis has increased over time. 1 There are several groups of nephrology patients with high risk of infection, and therefore, with higher prevalence than that commonly observed in general population. The prevalence of HCV infection among hemodialysis patients varied between countries. In the DOPPS study, the mean prevalence was 13.5% and varied among sites from 2.6% to 22.9%. 2 Prevalence rates are also variable in kidney-transplant recipients ranging from 7% to 40%. 2 Patients with end stage renal disease (ESRD) and kidney transplant recipients have been considered for HCV treatment with high priority in most international guidelines. 3, 4 Little information exists on treatment in patients with earlier stages of chronic kidney disease (CKD) where CKD progression might be slowed by HCV treatment. Although some guidelines propose universal treatment, others are still recommending it only in high priority groups. 3, 4 In this review, we evaluate current evidence of the benefits of HCV infection treatment in patients with mild to moderate CKD. 
HCV AS A SYSTEMIC DISEASE
HCV infection has been typically appreciated as a hepatic disease with morbidity and mortality mainly related to decompensated cirrhosis or HCC. Currently, however, more attention is being paid to extrahepatic manifestations of HCV, due to their significant non-liver related morbidity and mortality. 5 Besides the liver, HCV can affect almost every organ mainly kidneys, skin, thyroid, eyes, joints, central and peripheral nervous systems, and immune system. 6 Some of these extra hepatic manifestations are clearly related to HCV infection including Mixed Cryoglobulinemia Syndrome, B cell lymphoma, glomerulonephritis, porphyria cutanea tarda, lichen planus, and polyarthritis. Other common diseases such as type 2 diabetes mellitus (DM), CKD, cardiovascular diseases (CVD), and neurocognitive impairment, are increasingly recognized as extrahepatic manifestations due to their strong association with HCV. 5, 6 
DM AND HCV
Multiple studies have shown a higher risk of DM in HCVinfected patients. Furthermore, HCV treatment has been associated with a reduced risk of developing DM. 6 The REVEAL study followed 21,559 adults for almost 20 years and reported a cumulative risk for DM of 16.7% in HCV infected patients when compared to 10.9% in uninfected persons. 7 After adjustment, the hazard ratio (HR) for developing DM in viremic patients was 1.63 (95% confidence interval [CI] 1.31-2.02, P < 0.01). 7 While other studies have not found a relationship between HCV infection and DM risk, a recent meta-analysis of 34 studies including over 200,000 patients supported this association. 8, 9 Data from the interferon (IFN) era demonstrated that sustained virological response (SVR) was associated with reduced risk of developing insulin resistance, improved glycemic control, and a reduced occurrence of ESRD, ischemic stroke, and acute coronary syndrome in DM patients. 10, 11 More recently, treatment with the IFN free direct-acting antiviral agents (DAAs) has also been associated with better outcomes in HCV-infected patients with DM: improved glycemic control as evidenced by decreased in mean HbA1c, in the use of antidiabetic medications and in insulin had been reported in patients achieving SVR. 12, 13 Several mechanisms had been proposed to explain HCV role for the increased risk of DM development. 9 The main possible mechanisms are: a direct role of the virus (HCV core protein leads to negative interaction with insulin signaling and may cause derangement in glucosestimulated insulin release through b-cell dysregulation); host response to the virus (increased hepatic levels of proinflammatory cytokines may lead to altered hepatic sensitivity to insulin); and as a consequence of HCV-induced liver damage (advanced fibrosis or cirrhosis may induce dysregulation of glycemic control). 9 
CARDIOVASCULAR DISEASE AND HCV
Similar uncertainty exists regarding the association between CVD and HCV.
14 However, a recent metaanalysis showed that HCV infected patients are at an increased risk of CVD-related mortality (odds ratio [OR], 1.65; 95% CI, 1.07-2.56; P 5 0.02), carotid plaques (OR, 2.27; 95% CI, 1.76-2.94; P < 0.001), and cerebrovascular events (OR, 1.30; 95% CI, 1.10-1.55; P 5 0.002). 15 The effect of HCV infection on CVD was increased in populations with higher prevalence of DM. 15 Achieving SVR with IFN-based antiviral therapy is associated with improved CVD outcomes. 11, 16 As seen in patients with DM, achieving SVR after treatment with DAAs is also associated with improved CVD outcomes. 17 Studies with short term follow up showed reduced triglycerides levels at the end of treatment when compared to baseline levels. 17 Long-term follow-up studies with DAAs are needed to demonstrate the clinical benefit of this reduction.
DM and CVD are well recognized factors associated with increased risk of CKD. In HCV infected patients, they may have a combined impact for a higher risk of CKD development and progression. Therefore, it is conceivable that eradication of HCV through DAA treatment may lead to improved DM and CVD outcomes and possibly result in a reduction in the incidence and progression of CKD irrespective of whether HCV-associated glomerulonephritis is present or not.
HCV AND RISK OF CKD PROGRESSION
HCV infection has been linked to higher incidences of microalbuminuria and decreased estimated glomerular filtration rate (eGFR), an increased risk of CKD progression and higher risk of kidney-related mortality. In a metaanalysis that included 890,560 individuals, anti-HCV seropositive status was associated with a 70% increased risk of eGFR <60 mL/min/1.73 m 2 (adjusted relative risk, 1.70; 95% CI, 1.20-2.39; P 5 0.002). 18 In the REVEAL study, HCV infected individuals had a lower eGFR (85.0 6 18.0 mL/min/1.73 m 2 vs. 89.7 6 20.0 mL/min/ 1.73 m 2 , P < 0.001) and an increased risk of developing ESRD (HR, 2.33, 95% CI 1.40-3.89; P < 0.001) when compared with noninfected individuals. 19 These results were confirmed by a US veterans cohort, where chronic HCV infection was associated with higher risk of newonset eGFR <60 mL/min/1.73 m 2 (HR 1.11, 95% CI 1.09-1.13), of rapid deterioration of kidney function, defined as reduction in eGFR >5 mL/min/1.73 m 2 (OR 1.64, 95% CI 1.60-1.68), and development of ESRD (HR 3.50, 95% CI 3.25-3.78). 20 Data from NHANES III determined that the prevalence of microalbuminuria in patients with HCV was significantly higher when compared to noninfected individuals (12.4% vs. 7.5%, respectively; P 5 0.001). 21 In a meta-analysis including nine clinical studies and 817,917 individuals, in HCV positive patients the relative risk of developing proteinuria was 1.47 (95% CI, 1.12-1.94; P 5 0.006). 22 The pathogenesis of HCV-related kidney diseases is multifactorial and may result from immune-mediated and or HCV direct kidney damage. 23 Other factors likely involved with the higher risk of kidney progressive damage in HCVinfected patients are age, race, genetics, and the presence of DM and CVD. 24 Kidney disease is another relevant extrahepatic manifestations associated with HCV infection. 6 Membranoproliferative glomerulonephritis (MPGN) is the classical manifestation of MC-associated nephropathy 23 in a patient with skin vasculitis and arthritis. In addition, there may be isolated kidney damage without the MC syndrome. In these cases, MPGN is the most common presentation, with mesangial and diffuse proliferative GN less frequently seen. Finally, tubulointerstitial nephritis, membranous GN, and IgA nephropathy can be rarely seen. 23 
WINDOW OF OPPORTUNITY: TREAT NOW BEFORE IS TOO LATE
Historically, the goal of HCV treatment has been to eradicate the infection and to prevent liver-related complications such as cirrhosis, HCC, and liver related death. Today, with the advent of the new DAA, more attention has been paid to other treatment goals such a prevention of the development or clinical improvement of DM, CVD, and CKD. These achievements are independent of the severity of liver disease and are aligned with the current trend toward universal treatment of HCV proposed by World Health Organization. 1 Universal treatment irrespective of liver disease severity will prevent or reduce the development of EHMs associated with HCV chronic infection.
Eradicating HCV infection with IFN-based therapy (IBT) has been associated with a reduced risk of all-cause mortality, liver-related mortality, liver transplantation, liver failure, and HCC. 25 An improvement in almost all extrahepatic manifestations was also achieved with SVR. 26 Regarding kidney disease, in most studies, SVR has been associated with reduced incidence of CKD, reduced risk of CKD progression, reduced incidence of ESRD, and improvement in eGFR. 11, [27] [28] [29] [30] During 8 years in Taiwan (2003-2011) , 1411 patients treated with IBT were followed. The cumulative incidences of ESRD in the treated, untreated, and uninfected cohorts were 1.1% (95% CI, 0.3%-2.0%), 9.3% (95% CI, 5.9%-12.7%), and 3.3% (95% CI, 2.3%-4.3%), respectively (P < 0.001).
11 In Japan, 650 cirrhotic patients treated with IBT were evaluated. Eighty-five patients developed CKD, and six patients progressed to end-stage-CKD. The development rate of CKD was 5.2% at the 5th year, 14.5% at the 10th year, and 30.6% at the 15th year. The annual incidence for CKD was 1.0% to 1.5%. Not achieving SVR was associated with an increased risk of CKD: HR 2.67; 95% CI 1.34-5.32%; P 5 0.005). 27 Another study from Taiwan compared 919 IBT treated patients with 3676 untreated controls. In the treated cohort, the risk of CKD was significantly lower: 7-year cumulative incidence, 2.6%; 95% CI, 0.7%-6.9% vs. 4%; 95% CI, 3.5%-5.2%), with an adjusted HR of 0.42 (95% CI, 0.20-0.92; P 5 0.03). The calculated 8-year cumulative incidence of ESRD was 0.15% in treated vs. 1.32% in untreated patients (P < 0.001). IBT was associated with lower risks of ESRD (HR 0.15; 95% CI 0.07-0.31; P < 0.001). 29 On the contrary, in a study 1676 HIV/HCV-coinfected patients, SVR was not associated with a lower risk of CKD. 30 The magnitude of these benefits varies between the different studies, but all of them are maintained over time. IBT has been used for decades and the main challenge is to know if the same benefits can be obtained with DAA.
Despite the short time that DAAs are on the market, they have shown an improvement in almost all extrahepatic manifestations. [31] [32] [33] Among patients with baseline eGFR <90 mL/min/1.73 m 2 , achieving SVR with DAAs is associated with a significant improvement in eGFR: it increased from 77.81 mL/min/1.73 m 2 at baseline up to 82.36 mL/ min/1.73 m 2 post SVR (P 5 0.014). 34 Pooled results of phase 3 trials using ritonavir-boosted paritaprevir, plus ombitasvir, and dasabuvir (PROD) reported an improvement in eGFR in patients with CKD stages 2 and 3, 12 weeks after SVR eGFR improved 2.15 mL/min/1.73 m 2 (P 5 0.0003) and 7.92 mL/min/1.73 m 2 (P 5 0.0035) when compared to baseline, respectively. 35 36 A similar study from the US analyzed 1042 patients who underwent HCV therapy with different DAAs combinations showed significant benefit in eGFR only in patients with CKD stages 3 and 4. 37 Patients with CKD stages 3 and 4 had a 10% and 20% increase in eGFR, respectively, when compared with baseline values (P < 0.01). Improvement in eGFR was maintained over time, including patients who experienced a virologic relapse.
37 Surprisingly, the impact of DAA therapy in patients with CKD stage 2 had a negative impact on eGFR with a 3.1% (P < 0.01) reduction compared with pre-treatment. 37 This change in eGFR in stage 2 CKD (eGFR 60-90 mL/min/1.73 m 2 ) might not be clinically significant and might occur solely because a small change in serum creatinine often leads to a large change in eGFR at these low serum creatinine/high GFR values.
DAA treatment may also prevent progression to ESRD. In a large US cohort, 19,606 HCV treated patients were compared with 138,058 untreated HCV patients. Treated patients had a reduced risk of ESRD compared to untreated (RR 5 0.56, 95% CI: 0.46-0.67). Furthermore, a reduction in the risk of ESRD was also observed when analyses were restricted to patients with prior CKD diagnosis after adjustment for baseline CKD stage, though not statistically significant (RR 5 0.76, 95% CI: 0.55-1.04). 38 
CURRENT REGIMENS AVAILABLE FOR PATIENTS CKD
Several DAAs regimens have been approved for the treatment of HCV, with three different mechanisms of actions that target 3 nonstructural proteins: NS5A, NS3/4A, and NS5B (nucleoside and non-nucleoside). SOF, an NS5B nucleoside polymerase inhibitor, is the only DAA with significant renal elimination and it is contraindicated in patients with eGFR <30 mL/min/1.73 m 2 . The remainder of the DAAs are metabolized by the liver do not require dose adjustment in advanced CKD or in dialysis. Currently, there are many DAAs regimens available worldwide: SOF/ LDV; SOF plus velpatasvir (SOF/VEL); SOF/VEL plus voxilaprevir (SOF/VEL/VOX); PROD; glecaprevir plus pibrentasvir (GP); elbasvir plus grazoprevir (EBR/GZR); DCV; and SMV. There are many recommendations about their use in the different clinical scenarios and discussing each one is beyond the scope of this review. 3, 4 Several of these regimens can be used in patients with CKD stages 4 and 5, previously considered difficult to treat populations.
Less attention has been paid to the treatment of patients with CKD stages 2 and 3. Different randomized clinical trials (RCTs) and real-life cohorts have demonstrated the efficacy of different DAA combinations in CKD patients. 39 Today, patient and viral characteristics have little or no impact on SVR rates which is high across nearly all patient populations, HCV genotypes, and treatment regimens. As a result, increased attention is being focused on safety.
Most RCT of DAA in the general population included patients with normal renal function, and trials for patients with CKD primarily included CKD stage 4 and 5 patients. Therefore, information about treatment safety in CKD patients is based on post marketing and real-world studies. 40 Recently, many results have been presented at international meetings in abstract format related to this topic. The TRIO Network reported their real-world experience in 440 patients with chronic HCV infection treated with EBR/GZR. 41 Patient distribution according to CKD stages 2, 3, 4, and 5 was: 25%, 20%; 10% and 45%; respectively. In patients with CKD, HCV genotypes were: 1a 59%, 1b 35%, 4 5%, and unknown 1%. SVR rates were 94% (34/36) in CKD stage 2 and 100% (27/27) in CKD stage 3. There were no adverse events or decrease in eGFR reported. 41 The EBR/GZR regimen was evaluated in CKD patients treated in the US VA system. 42 SVR rate was 97.1% (758/781) in CKD stage 3 patients with no worsening of eGFR or serious adverse events reported. 42 These data suggest that EBR/GZR is effective, safe, and well tolerated in HCV-GT1-infected patients with CKD stages 2 and 3. Another real-life cohort included pooled analysis of 2220 patients treated with the PROD regimen at 287 academic centers in 12 countries, among which 33% had CKD (defined as creatinine clearance <90 mL/ min). In this retrospective report, CKD stages were classified according with the Common Terminology Criteria for Adverse Events using the Cockcroft-Gault method. SVR rates were 97% (299/309) in Grade 1 (60-75 mL/ min/1.73 m . 43 A grade 3 or 4 increase in serum creatinine occurred in 1.5% of the patients (33/2220). 44 SVR rates achieved in patients with CKD stages 2 and 3 in these studies, are similar to those reported in patients with CKD stages 4 and 5 and in patients without CKD. 3, 4 The HCV-TARGET database analyzed 1789 patients treated with SOF-based regimens in real-life conditions. The authors found no differences in SVR rates when comparing different stages of CKD. 45 However, worsening in renal function was reported in 2% (29/1789) 45 In another recent study, 98 patients with CKD stages 1 to 3 were treated with SOF-based regimens (including SOF-RBV and SOF/pegylated-IFN). Overall, SVR rates were 81% and varied by regimen used and viral genotype but not by CKD stage.
46 Seven (7.1%) patients experienced a greater than 1.5-fold increase in serum creatinine by while taking SOF, with values returning to baseline levels in all but one patient. 46 The safety of SOF in patients with CKD is still a matter of debate. So far, we only have information from a few case series with limited number of patients and different doses and frequency of administration of SOF.
47-49

RISK OF KIDNEY INJURY WITH DAAs
Treatment with DAA regimens in HCV patients with mild CKD are highly effective and also appear to slow CKD progression and possibly improve kidney function as well. Although RCT do not report any safety concern regarding kidney function, we should take into account that patients included in these trials have normal kidney function and have gone through a rigorous selection process to include almost "ideal" candidates. 40 Some studies described above report that kidney function may deteriorate, particularly with SOF-based regimens and in cirrhotic patients and patients with baseline CKD stage 3. 36, 48, 49 Conversely, a study using SOF in patients with mild to moderate renal dysfunction (CKD stages 2 and 3) found no changes in patients' eGFR from baseline to 12 weeks post therapy. 50 However, some controversy still exists highlighted by a recent report of 90 patients treated with PROD and SOFbased therapies. 51 A 10% increase in serum creatinine values was observed 24 weeks following the end of treatment (P < 0.0001). Worsening of kidney function occurred mainly during the first 4 weeks of treatment, and then stabilized, but did not return to baseline values after cessation of therapy. CKD patients developed worse acute kidney injury compared with those with normal renal function (33% vs. 9%, P 5 0.029). Importantly, patients who received ACE inhibitors or angiotensin II receptor antagonists had significantly more renal impairment than those not receiving these antihypertensive drugs (17% vs. 6%, P 5 0.028). The type of DAA combination used did not influence the renal impairment seen, nor did the use of RBV. 51 In the electronically retrieved cohort of HCV infected veterans (ERCHIVES) cohort, the impact of DAAs on eGFR was evaluated retrospectively. 52 In 3899 patients treated with SOF/LDV 6 RBV, a >10 mL/min/1.73 m , and 0% with baseline eGFR of <30 mL/ min/1.73 m 2 (P < 0.01). 52 Finally, results from the pooled analysis of the RCT of the recently FDA-approved regimen GP including 1665 patients showed no statistical change in eGFR (0.47 mL/min/1.72 m 2 ) at 4 weeks posttreatment compared with baseline values. 17 
CONCLUSIONS
However, treatment provides an opportunity of halting disease progression and improvement of kidney function with most regimens. Although there is a low risk of eGFR deterioration, it occurs more frequently with SOF-based therapies in the subgroup of patients with CKD stages 2 and 3. Nevertheless, there appears to be a real benefit in treating CKD patient population.
An important caveat in the CKD population is that treatment uptake is very low: only 8.8% of patients with CKD were treated in the ERCHIVES cohort, and persons with more advanced CKD were significantly less likely to initiate treatment (OR 0.28 for CKD stages 4-5; 0.66 for CKD stage 3; comparison group eGFR 60 mL/min/ 1.73 m 2 ). 53 Patients with earlier stages of CKD should be treated promptly regardless the severity of liver disease, with close monitoring of kidney function, to potentially slow CKD progression.
Even these are good news, there is still a lot of work to be done. Most studies reporting results with DAAs have a short term follow up. Longer duration studies, as those for IBT, are needed to corroborate these results. Also, complete information is about DAAs treatment is needed since most results were presented as abstracts and the full text version of them is not yet available.
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